Sean Park

Has grant

Professor

Mayo Clinic Rochester
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Sean Park is a Professor at Mayo Clinic Rochester in the United States. His research areas include radiotherapy techniques, particularly for renal cell carcinoma and prostate cancer, as well as interventions in musculoskeletal oncology. His recent articles focus on innovative methods in MR simulation and the application of antiandrogens in cancer treatment. He is actively involved in advancing clinical practices through rigorous research in radiation therapy.

Recent Grants

Grant: Open

Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma

Open Date: 2024-09-01

Close Date: 2029-08-31

Grant: Open

Radiation and dendritic cells to hepatomas to improve immunotherapy response

Open Date: 2022-09-01

Close Date: 2027-08-31

Grant: Close

Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma

Open Date: 2021-02-05

Close Date: 2023-01-31

Grant: Close

A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR

Open Date: 2016-02-09

Close Date: 2019-01-31

Articles (26)

Year:

2026

Year:

2026

Year:

2026

Purpose: Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong androgen-deprivation therapy–free survival or progression-free survival (PFS) in patients with metachronous oligometastatic castration-sensitive prostate cancer (omCSPC). Although most patients with omCSPC have a more modest delay in progression, a small subset achieves a durable response following SABR. We investigated the prognostic and predictive value of circulating prostate-specific membrane antigen-positive (PSMA + ) extracellular vesicles (EV) and PSA in a biomarker correlative study using blood samples from three independent patient cohorts. Experimental Design: Plasma samples from 46 patients with omCSPC on the ORIOLE trial and 127 patients with omCSPC on the STOMP trial protocol treated with SABR were included in the study. Pre-SABR PSMA + EV levels (EV/mL) were measured by nanoscale flow cytometry. Kaplan–Meier curves and logistic regression models were used to determine the association of PSMA + EV and PSA levels with clinical outcomes. Results: In the pooled cohorts, the median biochemical PFS were 26.1 and 15.0 months ( P = 0.005), and the median radiographic PFS were 36.0 and 25.0 months ( P = 0.003) for PSMA + EV-low and -high groups, respectively. The combination of pre-SABR low levels of both PSMA + EV and PSA was associated with a lower risk of radiographic progression (HR, 0.34, 95% confidence interval, 0.18–0.58; P = 0.0002). In the ORIOLE cohort, which included both an SABR arm and an observation arm, low PSMA + EV was predictive of benefit from SABR ( P = 0.012). Conclusions: PSMA + EV is a novel prognostic and predictive biomarker of radiographically occult tumor burden in omCSPC. PSMA + EV may inform clinical decisions about identifying patients who will achieve a durable benefit from consolidative SABR alone.

Year:

2025

Immune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance. We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation and overcome ICI resistance. Patients with metastatic ICI-resistant melanoma and elevated sPD-L1 received radiotherapy to a minority of metastatic lesions, TPE, and ICI re-challenge. Primary endpoints were adverse events and sPD-L1 reduction. Secondary endpoints included overall survival, response, and progression-free survival. Correlative studies included changes in sPD-L1, other immunosuppressive factors, and immune cell phenotypes. Eighteen patients were included. Treatment was well-tolerated, and levels of sPD-L1 were reduced by TPE (mean 78%, p < 0.0001). Soluble PD-L1 suppression predicted overall survival. The overall response rate was 61% (16.7% complete, 44.4% partial, 22.2% stable, and 16.7% progressing). Changes in peripheral immune cell populations and immunosuppressive factors predicted overall survival. sPD-L1 and other circulating immunoregulatory molecules mediate ICI resistance. TPE can reduce these factors and resensitize ICI-refractory melanoma. Patients with persistent elevation or rapid rebound of sPD-L1 experienced inferior outcomes, suggesting that multiple courses of TPE may be necessary. These findings may apply to other ICI-resistant cancers. Trial registration: NCT04581382, ReCIPE-M1 (Rescuing Cancer Immunotherapy with Plasma Exchange in Melanoma 1).

Year:

2025

Supplementary Figure S11. Cell-free DNA methylation levels of the top 10 least stem-like signature genes in plasma. The box and whisker plots summarize the promoter methylation rates for the top 10 least stem-like genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.

Year:

2025

Supplementary Figure S7. Distribution of differentially methylated regions in mCRPC plasma cell-free DNA. (A) Distribution of hypomethylated and hypermethylated genic DMRs in pre-treatment plasma cfDNA in AR /enhancer altered lethal mCRPC (compared to AR /enhancer wild-type mCRPC). (B) Genomic annotation of genic DMRs based on their location in the genome. (C) Top 50 hypermethylated DMRs found in pre-treatment plasma cfDNA from AR /enhancer altered lethal mCRPC patients (compared to AR /enhancer wild-type mCRPC). cfDNA, cell-free DNA; CDS, coding sequence; DMRs, differentially methylated regions; mCRPC, metastatic castration-resistant prostate cancer; UTR, untranslated region.

Year:

2025

Supplementary Figure S2. Kaplan-Meier analysis based on plasma collected prior to first-line androgen receptor-signaling inhibitor (ARSI) treatment according to (A,B) Androgen receptor ( AR ) gene body status and (C,D) AR enhancer region status in 63 patients with metastatic castration-resistant prostate cancer (mCRPC). p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method.

Year:

2025

Supplementary Figure S10. Cell-free DNA methylation levels of the top 10 most stem-like signature genes in plasma. The box and whisker plots summarize promoter methylation rates for the top 10 most stem-like signature genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.

Year:

2025

Supplementary Figure S1. Genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) samples profiled using EnhanceAR-Seq. EnhanceAR-Seq, Enhancer and neighboring loci of Androgen Receptor Sequencing.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (20)

Oliver Sartor

Tulane University School of Medicine

UNITED STATES
View details

Phuoc T. Tran

University of Maryland

UNITED STATES
View details

Sundeep Khosla

Mayo Clinic

UNITED STATES
View details

Liguo Wang

Professor of Biomedical Informatics

Mayo Clinic Minnesota

UNITED STATES
View details

Daniel D. Billadeau

-

UNITED STATES
View details

Xianfang Wu

Associate Professor/Staff

Cleveland Clinic

UNITED STATES
View details

Jace Webster

Full Specialist

University of California, San Francisco

UNITED STATES
View details

Xu Zhang

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Aaron Mansfield

Mayo Clinic Minnesota

UNITED STATES
View details

Robert McWilliams

Mayo Clinic Minnesota

UNITED STATES
View details

Piet Ost

Ghent University

BELGIUM
View details

Peter Harris

Staff Scientist

Washington University in St. Louis

UNITED STATES
View details

Aadel A. Chaudhuri

Washington University School of Medicine

UNITED STATES
View details

Haidong Dong

Professor/Consultant

Mayo Clinic Rochester

UNITED STATES
View details

Jacob Orme

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Pradeep Chauhan

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Fabrice Lucien

Assistant Professor

Mayo Clinic Minnesota

UNITED STATES
View details

Minetta Liu

Research Collaborator, Professor

Mayo Clinic

UNITED STATES
View details

Russell K. Pachynski

Washington University School of Medicine

UNITED STATES
View details

Christopher A Maher

Washington University in St. Louis

UNITED STATES
View details